David Matheson

5PUBLICATIONS
61CO-AUTHORS
Epidemiological modellingPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.

Nicholas D James, Fiona C Ingleby, Noel W Clarke

|Jun 07, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.

Chris C Parker, Nicholas D James, Christopher D Brawley

|Jun 02, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.

Caroline S Clarke, Rachael M Hunter, Andrea Gabrio

|Apr 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Nicholas D James, Noel W Clarke, Adrian Cook

|Nov 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.

Hannah L Rush, Laura Murphy, Alicia K Morgans

Pageof 1

Frequent Collaborators

5 joint publications

Nicholas D James

5 joint publications

Hannah Rush

5 joint publications

Robert J Jones

5 joint publications

Matthew R Sydes